Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis.
a Division of Nephrology and Hypertension , Mayo Clinic , Rochester , MN , USA.
Abdurrahman M
AM
Hamadah
b Division of Hematology , Mayo Clinic , Rochester , MN , USA.
Gita
G
Thanarajasingam
a Division of Nephrology and Hypertension , Mayo Clinic , Rochester , MN , USA.
Kamel A
KA
Gharaibeh
b Division of Hematology , Mayo Clinic , Rochester , MN , USA.
Heidi D
HD
Finnes
b Division of Hematology , Mayo Clinic , Rochester , MN , USA.
Carrie A
CA
Thompson
a Division of Nephrology and Hypertension , Mayo Clinic , Rochester , MN , USA.
Nelson
N
Leung
D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy*; D008223:Lymphoma / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D006435:Renal Dialysis; D017211:Treatment Failure; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide